

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

March 9, 2022

Danny Yeung Director Prenetics Global Limited Unit 701-706, K11 Atelier King's Road 728 King's Road, Quarry Bay, Hong Kong

# Re: Prenetics Global Limited Amendment No. 7 to Registration Statement on Form F-4 Filed March 4, 2022 File No. 333-260928

Dear Mr. Yeung:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

## Amendment No. 7 to Registration Statement on Form F-4

## Unaudited Pro Forma Condensed Combined Financial Information, page 279

1. Your disclosures on page 279 and 292 indicate that the historical financial information of Prenetics was derived from the audited financial statements for the period ended December 31, 2021 included elsewhere in the proxy statement/prospectus. This appears to be a typographical error. Please revise as necessary.

#### <u>General</u>

2. We note your responses to comments issued in our letter dated February 14, 2022. Please note we are continuing to consider these responses and corresponding revisions to your registration statement.

Danny Yeung Prenetics Global Limited March 9, 2022 Page 2

You may contact Nudrat Salik at 202-551-3692 or Mary Mast at 202-551-3613 if you have questions regarding comments on the financial statements and related matters. Please contact Alan Campbell at 202-551-4224 or Laura Crotty at 202-551-7614 with any other questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Jonathan B. Stone, Esq.